Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment (TTX-CINP-201)

This study has been terminated.
(Interim analysis completed and decided to terminate and proceed to Phase 3 trial.)
Information provided by (Responsible Party):
Wex Pharmaceuticals Inc. Identifier:
First received: July 19, 2012
Last updated: June 1, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)